Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Belldegrun, A; Tso, CL; Zisman, A; Naitoh, J; Said, J; Pantuck, AJ; Hinkel, A; de Kernion, J; Figlin, R
   Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology
   HUMAN GENE THERAPY
   
   A. Belldegrun et al., "Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology", HUM GENE TH, 12(8), 2001, pp. 883-892
2. Tso, CL; Zisman, A; Pantuck, A; Calilliw, R; Hernandez, JM; Paik, S; Nguyen, D; Gitlitz, B; Shintaku, PI; de Kernion, S; Figlin, R; Belldegrun, A
   Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 andGranulocyte/Monocyte-Colony stimulating factor
   CANCER RESEARCH
   
   C.L. Tso et al., "Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 andGranulocyte/Monocyte-Colony stimulating factor", CANCER RES, 61(21), 2001, pp. 7925-7933
3. Hinkel, A; Tso, CL; Gitlitz, BJ; Neagos, N; Schmid, I; Paik, SH; deKernion, J; Figlin, R; Belldegrun, A
   Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma
   JOURNAL OF IMMUNOTHERAPY
   
   A. Hinkel et al., "Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma", J IMMUNOTH, 23(1), 2000, pp. 83-93
4. Small, EJ; Figlin, R; Petrylak, D; Vaughn, DJ; Sartor, O; Horak, I; Pincus, R; Kremer, A; Bowden, C
   A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma
   INVESTIGATIONAL NEW DRUGS
   
   E.J. Small et al., "A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma", INV NEW DR, 18(2), 2000, pp. 193-197
5. Tsui, KH; Shvarts, O; Smith, RB; Figlin, R; DeKernion, JB; Belldegrun, A
   Renal cell carcinoma: Prognostic significance of incidentally detected tumors
   JOURNAL OF UROLOGY
   
   K.H. Tsui et al., "Renal cell carcinoma: Prognostic significance of incidentally detected tumors", J UROL, 163(2), 2000, pp. 426-430
6. Tsui, KH; Shvarts, O; Barbaric, Z; Figlin, R; DeKernion, JB; Belldegrun, A
   Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies
   JOURNAL OF UROLOGY
   
   K.H. Tsui et al., "Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies", J UROL, 163(2), 2000, pp. 437-441
7. Mulders, P; Tso, CL; Gitlitz, B; Kaboo, R; Hinkel, A; Frand, S; Kiertscher, S; Roth, MD; deKernion, J; Figlin, R; Belldegrun, A
   Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines
   CLINICAL CANCER RESEARCH
   
   P. Mulders et al., "Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: Implications for live kidney cancer vaccines", CLIN CANC R, 5(2), 1999, pp. 445-454
8. Cangiano, T; Liao, J; Naitoh, J; Dorey, F; Figlin, R; Belldegrun, A
   Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
   JOURNAL OF CLINICAL ONCOLOGY
   
   T. Cangiano et al., "Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy", J CL ONCOL, 17(2), 1999, pp. 523-528
9. Figlin, R
   Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. Comment
   JOURNAL OF UROLOGY
   
   R. Figlin, "Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. Comment", J UROL, 162(6), 1999, pp. 1937-1937
10. Naitoh, J; Kaplan, A; Dorey, F; Figlin, R; Belldegrun, A
    Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy
    JOURNAL OF UROLOGY
    
    J. Naitoh et al., "Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy", J UROL, 162(1), 1999, pp. 46-50
11. MULDERS P; TSO CL; PANG S; KABOO R; MCBRIDE WH; HINKEL A; GITLITZ B; DANNULL J; FIGLIN R; BELLDEGRUN A
    ADENOVIRUS-MEDIATED INTERLEUKIN-2 PRODUCTION BY TUMORS INDUCES GROWTHOF CYTOTOXIC TUMOR-INFILTRATING LYMPHOCYTES AGAINST HUMAN RENAL-CELL CARCINOMA
    Journal of immunotherapy
    
    P. Mulders et al., "ADENOVIRUS-MEDIATED INTERLEUKIN-2 PRODUCTION BY TUMORS INDUCES GROWTHOF CYTOTOXIC TUMOR-INFILTRATING LYMPHOCYTES AGAINST HUMAN RENAL-CELL CARCINOMA", Journal of immunotherapy, 21(3), 1998, pp. 170-180
12. VOKES EE; FIGLIN R; HOCHSTER H; LOTZE M; RYBAK ME
    A PHASE-II STUDY OF RECOMBINANT HUMAN INTERLEUKIN-4 FOR ADVANCED OR RECURRENT NONSMALL CELL LUNG-CANCER
    The cancer journal from Scientific American
    
    E.E. Vokes et al., "A PHASE-II STUDY OF RECOMBINANT HUMAN INTERLEUKIN-4 FOR ADVANCED OR RECURRENT NONSMALL CELL LUNG-CANCER", The cancer journal from Scientific American, 4(1), 1998, pp. 46-51
13. NAITOH J; KABOO R; TSO CL; HINKEL A; STILES A; FIGLIN R; BELLDEGRUN A
    IMMUNOLOGICAL EFFECTS OF INTERLEUKIN-2 (IL-2) GENE-THERAPY IN PROSTATE-CANCER (CAP)
    The Journal of urology
    
    J. Naitoh et al., "IMMUNOLOGICAL EFFECTS OF INTERLEUKIN-2 (IL-2) GENE-THERAPY IN PROSTATE-CANCER (CAP)", The Journal of urology, 159(5), 1998, pp. 47-47
14. CANGIANO TG; LIAO JL; NAITOH J; DOREY F; FIGLIN R; BELLDEGRUN A
    SARCOMATOID VARIANT RENAL-CELL CARCINOMA - BIOLOGIC BEHAVIOR, PROGNOSIS, AND RESPONSE TO COMBINED SURGICAL RESECTION AND ADJUVANT IMMUNOTHERAPY
    The Journal of urology
    
    T.G. Cangiano et al., "SARCOMATOID VARIANT RENAL-CELL CARCINOMA - BIOLOGIC BEHAVIOR, PROGNOSIS, AND RESPONSE TO COMBINED SURGICAL RESECTION AND ADJUVANT IMMUNOTHERAPY", The Journal of urology, 159(5), 1998, pp. 656-656
15. NAITOH J; TSO CL; KABOO R; STILES A; FIGLIN R; BELLDEGRUN A
    INTRAPROSTATIC INTERLEUKIN-2 (IL-2) GENE-THERAPY - PRELIMINARY-RESULTS OF A PHASE-I CLINICAL-TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED PROSTATE-CANCER (CAP)
    The Journal of urology
    
    J. Naitoh et al., "INTRAPROSTATIC INTERLEUKIN-2 (IL-2) GENE-THERAPY - PRELIMINARY-RESULTS OF A PHASE-I CLINICAL-TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED PROSTATE-CANCER (CAP)", The Journal of urology, 159(5), 1998, pp. 973-973
16. FIGLIN R; GITLITZ B; FRANKLIN J; DOREY F; MOLDAWER N; RAUSCH J; DEKERNION J; BELLDEGRUN A
    INTERLEUKIN-2-BASED IMMUNOTHERAPY FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA - AN ANALYSIS OF 203 CONSECUTIVELY TREATED PATIENTS
    The cancer journal from Scientific American
    
    R. Figlin et al., "INTERLEUKIN-2-BASED IMMUNOTHERAPY FOR THE TREATMENT OF METASTATIC RENAL-CELL CARCINOMA - AN ANALYSIS OF 203 CONSECUTIVELY TREATED PATIENTS", The cancer journal from Scientific American, 3, 1997, pp. 92-97
17. FIGLIN R; MULDERS P; GITLITZ B; BELLDEGRUN A
    CELLULAR THERAPY OF RENAL-CELL CARCINOMA PAST, PRESENT, FUTURE
    European journal of cancer
    
    R. Figlin et al., "CELLULAR THERAPY OF RENAL-CELL CARCINOMA PAST, PRESENT, FUTURE", European journal of cancer, 33, 1997, pp. 31-31
18. STEGER GG; GNANT MF; DJAVANMARD MP; MADER RM; JAKESZ R; PIERCE W; DEKERNION JB; FIGLIN R; BELLDEGRUN A
    THE IN-VITRO EFFECTS OF INTERLEUKIN-12 UPON TUMOR-INFILTRATING LYMPHOCYTES DERIVED FROM RENAL-CELL CARCINOMA
    Journal of cancer research and clinical oncology
    
    G.G. Steger et al., "THE IN-VITRO EFFECTS OF INTERLEUKIN-12 UPON TUMOR-INFILTRATING LYMPHOCYTES DERIVED FROM RENAL-CELL CARCINOMA", Journal of cancer research and clinical oncology, 123(6), 1997, pp. 317-324
19. FANUCCHI M; GLASPY J; CRAWFORD J; GARST J; FIGLIN R; SHERIDAN W; MENCHACA D; TOMITA D; OZER H; HARKER L
    EFFECTS OF POLYETHYLENE GLYCOL-CONJUGATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR ON PLATELET COUNTS AFTER CHEMOTHERAPY FOR LUNG-CANCER
    The New England journal of medicine
    
    M. Fanucchi et al., "EFFECTS OF POLYETHYLENE GLYCOL-CONJUGATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR ON PLATELET COUNTS AFTER CHEMOTHERAPY FOR LUNG-CANCER", The New England journal of medicine, 336(6), 1997, pp. 404-409
20. MULDERS P; FIGLIN R; DEKERNION JB; WILTROUT R; LINEHAN M; PARKINSON D; DEWOLF W; BELLDEGRUN A
    RENAL-CELL CARCINOMA - RECENT PROGRESS AND FUTURE-DIRECTIONS
    Cancer research
    
    P. Mulders et al., "RENAL-CELL CARCINOMA - RECENT PROGRESS AND FUTURE-DIRECTIONS", Cancer research, 57(22), 1997, pp. 5189-5195
21. BELLDEGRUN A; TSO CL; KABOO R; PANG S; PIERCE W; DEKERNION JB; FIGLIN R
    NATURAL IMMUNE REACTIVITY-ASSOCIATED THERAPEUTIC RESPONSE IN PATIENTSWITH METASTATIC RENAL-CELL CARCINOMA RECEIVING TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2-BASED THERAPY
    Journal of immunotherapy with emphasis on tumor immunology
    
    A. Belldegrun et al., "NATURAL IMMUNE REACTIVITY-ASSOCIATED THERAPEUTIC RESPONSE IN PATIENTSWITH METASTATIC RENAL-CELL CARCINOMA RECEIVING TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2-BASED THERAPY", Journal of immunotherapy with emphasis on tumor immunology, 19(2), 1996, pp. 149-161
22. GRECO FA; FIGLIN R; YORK M; EINHORN L; SCHILSKY R; MARSHALL EM; BUYS SS; FROIMTCHUK MJ; SCHULLER J; SCHUCHTER L; BUYSE M; RITTER L; MAN A; YAP AKL
    PHASE-III RANDOMIZED STUDY TO COMPARE INTERFERON ALFA-2A IN COMBINATION WITH FLUOROURACIL VERSUS FLUOROURACIL ALONE IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
    Journal of clinical oncology
    
    F.A. Greco et al., "PHASE-III RANDOMIZED STUDY TO COMPARE INTERFERON ALFA-2A IN COMBINATION WITH FLUOROURACIL VERSUS FLUOROURACIL ALONE IN PATIENTS WITH ADVANCED COLORECTAL-CANCER", Journal of clinical oncology, 14(10), 1996, pp. 2674-2681
23. ECONOMOU JS; BELLDEGRUN AS; GLASPY J; TOLOZA EM; FIGLIN R; HOBBS J; MELDON N; KABOO R; TSO CL; MILLER A; LAU R; MCBRIDE W; MOEN RC
    IN-VIVO TRAFFICKING OF ADOPTIVELY TRANSFERRED INTERLEUKIN-2 EXPANDED TUMOR-INFILTRATING LYMPHOCYTES AND PERIPHERAL-BLOOD LYMPHOCYTES - RESULTS OF A DOUBLE GENE MARKING TRIAL
    The Journal of clinical investigation
    
    J.S. Economou et al., "IN-VIVO TRAFFICKING OF ADOPTIVELY TRANSFERRED INTERLEUKIN-2 EXPANDED TUMOR-INFILTRATING LYMPHOCYTES AND PERIPHERAL-BLOOD LYMPHOCYTES - RESULTS OF A DOUBLE GENE MARKING TRIAL", The Journal of clinical investigation, 97(2), 1996, pp. 515-521
24. NISHIKUBO CY; KUNKEL LA; FIGLIN R; BELLDEGRUN A; ROSEN P; ELASHOFF R; WANG HJ; TERRITO MC
    AN ASSOCIATION BETWEEN RENAL-CELL CARCINOMA AND LYMPHOID MALIGNANCIES- A CASE SERIES OF 8 PATIENTS
    Cancer
    
    C.Y. Nishikubo et al., "AN ASSOCIATION BETWEEN RENAL-CELL CARCINOMA AND LYMPHOID MALIGNANCIES- A CASE SERIES OF 8 PATIENTS", Cancer, 78(11), 1996, pp. 2421-2426
25. WHITEHEAD RP; HAUSCHILD A; CHRISTOPHERS E; FIGLIN R
    DIABETES-MELLITUS IN CANCER-PATIENTS TREATED WITH COMBINATION INTERLEUKIN-2 AND ALPHA-INTERFERON
    Cancer biotherapy
    
    R.P. Whitehead et al., "DIABETES-MELLITUS IN CANCER-PATIENTS TREATED WITH COMBINATION INTERLEUKIN-2 AND ALPHA-INTERFERON", Cancer biotherapy, 10(1), 1995, pp. 45-51
26. ALBERTI W; ANDERSON G; BARTOLUCCI A; BELL D; VILLALBA JB; BRODIN O; CARDIELLO C; CARTEI F; CARTEI G; CELLERINO R; CHASTANG C; CORMIER Y; COX JD; CRINO L; CROWLEY J; DAUTZENBERG B; DEPIERRE A; DIETEMANN A; DILLMAN RO; DOI O; FELD R; FIGLIN R; GANZ PA; GREEN MR; GREGOR A; HELLE PA; HERNDON JE; HITOMI S; HOST H; IMAIZUMI M; JETT JR; JOHNSON D; KAASA S; KIMURA H; KLASTERSKY J; KONDO H; KREISMAN H; KRIS MG; KUNISHIMA K; KUWAHARA O; LAD TE; LAING AH; MACBETH F; MASAOKA A; MATTSON K; MINATEL E; MIRA JG; MORI T; MOUNTAIN CF; NIEDERLE N; NIIRANEN A; NOU E; PAGE W; PATER J; PIANTADOSI S; PISTERS KMW; PYRHONEN S; QUOIX E; RAPP E; ROWELL NP; SAHMOUD T; SAWAMURA K; SCHALLIER DCC; SCOTT C; SIMPSON J; STAGG M; TERAMATSU T; TROVO MG; TSUCHIYA R; TUMMARELLO D; VANHOUTTE P; VANZANDWIJK N; VINCENT RG; WADA H; WHITE JE; WILLIAMS CJ; WOODS RL; YAMAGUCHI Y; ARRIAGADA R; CARTMELLDAVIES J; GIRLING DJ; LECHEVALIER T; MARSONI S; PARMAR MKB; PIGNON JP; REKACEWICZ C; SOUHAMI RL; STEWART LA; TARAYRE M; TINAZZI A; TONI V
    CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS
    BMJ. British medical journal
    
    W. Alberti et al., "CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS", BMJ. British medical journal, 311(7010), 1995, pp. 899-909
27. TANEJA SS; PIERCE W; FIGLIN R; BELLDEGRUN A
    IMMUNOTHERAPY FOR RENAL-CELL CARCINOMA - THE ERA OF INTERLEUKIN-2-BASED TREATMENT
    Urology
    
    S.S. Taneja et al., "IMMUNOTHERAPY FOR RENAL-CELL CARCINOMA - THE ERA OF INTERLEUKIN-2-BASED TREATMENT", Urology, 45(6), 1995, pp. 911-924
28. BELLDEGRUN A; FRANKLIN JR; FIGLIN R
    COMMENTARY ON PROGNOSTIC FACTORS IN RENAL-CELL CARCINOMA
    The Journal of urology
    
    A. Belldegrun et al., "COMMENTARY ON PROGNOSTIC FACTORS IN RENAL-CELL CARCINOMA", The Journal of urology, 154(4), 1995, pp. 1274-1274
29. STEGER GG; KABOO R; DEKERNION JB; FIGLIN R; BELLDEGRUN A
    THE EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ON TUMOR-INFILTRATING LYMPHOCYTES FROM RENAL-CELL CARCINOMA
    British Journal of Cancer
    
    G.G. Steger et al., "THE EFFECTS OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ON TUMOR-INFILTRATING LYMPHOCYTES FROM RENAL-CELL CARCINOMA", British Journal of Cancer, 72(1), 1995, pp. 101-107
30. TANEJA SS; PIERCE W; FIGLIN R; BELLDEGRUN A
    MANAGEMENT OF DISSEMINATED KIDNEY CANCER
    Urologic clinics of North America
    
    S.S. Taneja et al., "MANAGEMENT OF DISSEMINATED KIDNEY CANCER", Urologic clinics of North America, 21(4), 1994, pp. 625-637
31. STEGER GG; PIERCE WC; FIGLIN R; CZERNIN J; KABOO R; DEKERNION JB; OKARMA T; BELLDEGRUN A
    PATTERNS OF CYTOKINE RELEASE OF UNSELECTED AND CD8-CELL CARCINOMA TUMOR-INFILTRATING LYMPHOCYTES (TIL) - EVIDENCE FOR ENHANCED SPECIFIC KILLING OF TUMOR NECROSIS FACTOR-SECRETING IL-6 NONSECRETING TIL IN-VITROAND CORRELATION WITH COMPLETE RESPONSE IN-VIVO( SELECTED RENAL)
    Clinical immunology and immunopathology
    
    G.G. Steger et al., "PATTERNS OF CYTOKINE RELEASE OF UNSELECTED AND CD8-CELL CARCINOMA TUMOR-INFILTRATING LYMPHOCYTES (TIL) - EVIDENCE FOR ENHANCED SPECIFIC KILLING OF TUMOR NECROSIS FACTOR-SECRETING IL-6 NONSECRETING TIL IN-VITROAND CORRELATION WITH COMPLETE RESPONSE IN-VIVO( SELECTED RENAL)", Clinical immunology and immunopathology, 72(2), 1994, pp. 237-247
32. FIGLIN R; MENDOZA E; PIANTADOSI S; RUSCH V
    INTRAPLEURAL CHEMOTHERAPY WITHOUT PLEURODESIS FOR MALIGNANT PLEURAL EFFUSIONS - LCSG TRIAL-861
    Chest
    
    R. Figlin et al., "INTRAPLEURAL CHEMOTHERAPY WITHOUT PLEURODESIS FOR MALIGNANT PLEURAL EFFUSIONS - LCSG TRIAL-861", Chest, 106(6), 1994, pp. 190000363-190000366
33. HATHORN RW; TSO CL; KABOO R; PANG S; FIGLIN R; SAWYERS C; DEKERNION JB; BELLDEGRUN A
    IN-VITRO MODULATION OF THE INVASIVE AND METASTATIC POTENTIALS OF HUMAN RENAL-CELL CARCINOMA BY INTERLEUKIN-2 AND OR INTERFERON-ALPHA GENE-TRANSFER/
    Cancer
    
    R.W. Hathorn et al., "IN-VITRO MODULATION OF THE INVASIVE AND METASTATIC POTENTIALS OF HUMAN RENAL-CELL CARCINOMA BY INTERLEUKIN-2 AND OR INTERFERON-ALPHA GENE-TRANSFER/", Cancer, 74(7), 1994, pp. 1904-1911
34. ABIAAD AS; STENZL A; FIGLIN R; DEKERNION JB
    LOCAL RESPONSE AND LONG-TERM RESULTS OF PREOPERATIVE M-VAC REGIMEN INREGIONALLY ADVANCED TRANSITIONAL CELL-CARCINOMA OF THE BLADDER
    European journal of cancer
    
    A.S. Abiaad et al., "LOCAL RESPONSE AND LONG-TERM RESULTS OF PREOPERATIVE M-VAC REGIMEN INREGIONALLY ADVANCED TRANSITIONAL CELL-CARCINOMA OF THE BLADDER", European journal of cancer, 29A(8), 1993, pp. 1223-1224
35. BELLDEGRUN A; PIERCE W; KABOO R; TSO CL; SHAU HY; TURCILLO P; MOLDAWER N; GOLUB S; DEKERNION J; FIGLIN R
    INTERFERON-ALPHA PRIMED TUMOR-INFILTRATING LYMPHOCYTES COMBINED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA AS THERAPY FOR METASTATIC RENAL-CELL CARCINOMA
    The Journal of urology
    
    A. Belldegrun et al., "INTERFERON-ALPHA PRIMED TUMOR-INFILTRATING LYMPHOCYTES COMBINED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA AS THERAPY FOR METASTATIC RENAL-CELL CARCINOMA", The Journal of urology, 150(5), 1993, pp. 1384-1390
36. BELLDEGRUN A; PIERCE W; KABOO R; TSO CL; SHAU HY; TURCILLO D; MOLDAWER N; GOLLIB S; DEKERNION J; FIGLIN R
    THERAPY FOR METASTATIC RENAL-CELL CARCINOMA COMBINED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA AS INTERFERON-ALPHA PRIMED TUMOR-INFILTRATING LYMPHOCYTES - REPLY
    The Journal of urology
    
    A. Belldegrun et al., "THERAPY FOR METASTATIC RENAL-CELL CARCINOMA COMBINED WITH INTERLEUKIN-2 AND INTERFERON-ALPHA AS INTERFERON-ALPHA PRIMED TUMOR-INFILTRATING LYMPHOCYTES - REPLY", The Journal of urology, 150(5), 1993, pp. 1390-1390
37. JANIK JE; SZNOL M; URBA WJ; FIGLIN R; BUKOWSKI RM; FYFE G; PIERCE WC; BELLDEGRUN A; SHARFMAN WH; SMITH JW; LONGO DL
    ERYTHROPOIETIN PRODUCTION - A POTENTIAL MARKER FOR INTERLEUKIN-2 INTERFERON-RESPONSIVE TUMORS
    Cancer
    
    J.E. Janik et al., "ERYTHROPOIETIN PRODUCTION - A POTENTIAL MARKER FOR INTERLEUKIN-2 INTERFERON-RESPONSIVE TUMORS", Cancer, 72(9), 1993, pp. 2656-2659
38. CRAWFORD J; FIGLIN R; CHANG A; HAMM J; WASSERHEIT C; LEE M; CAMPION M; MANFREDA S; ISAACS R
    PHASE-I II TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-6 (RHIL-6) AND GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) FOLLOWING IFOSPHAMIDE, CARBOPLATIN AND ETOPOSIDE (ICE) CHEMOTHERAPY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CARCINOMA (NSCLC)/
    Blood
    
    J. Crawford et al., "PHASE-I II TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-6 (RHIL-6) AND GRANULOCYTE-COLONY-STIMULATING FACTOR (RHG-CSF) FOLLOWING IFOSPHAMIDE, CARBOPLATIN AND ETOPOSIDE (ICE) CHEMOTHERAPY IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CARCINOMA (NSCLC)/", Blood, 82(10), 1993, pp. 10000367-10000367